The global exosome diagnostics market is witnessing extraordinary growth as exosome-based technologies emerge as a breakthrough in precision medicine and liquid biopsy testing. The market is projected to surge from USD 59 million in 2024 to USD 2,347 million by 2029, registering an exceptional CAGR of 108.9% during the forecast period.
While exosome therapeutics are still in the development stage and expected to launch commercially from 2029 onward, the combined exosome diagnostics and therapeutics market is forecast to grow from USD 59 million in 2024 to USD 6,848 million by 2032 at a CAGR of 81.2%.
The rapid market expansion is driven by increasing demand for non-invasive cancer diagnostics, advancements in liquid biopsy technologies, and rising investments in precision oncology research. Exosomes—tiny extracellular vesicles released by cells—are gaining significant attention for their ability to carry biomarkers that support early disease detection, treatment monitoring, and targeted therapy development.
Currently, the market remains highly monopolized, with Bio-Techne standing as the only company offering approved and commercialized exosome-based diagnostic tests.
Key companies operating in the exosome diagnostics and therapeutics market include Bio-Techne, NanoFCM Inc., System Biosciences, LLC., Capital Biosciences, Inc., AMSBIO, INOVIQ, Direct Biologics LLC, Regeneus Ltd, CUREXSYS, and Aegle Therapeutics.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198025144
Bio-Techne Dominates the Commercial Exosome Diagnostics Space
Bio-Techne currently leads the exosome diagnostics market due to its early commercialization success and strong focus on liquid biopsy technologies. The company entered the exosome diagnostics space through the acquisition of Exosome Diagnostics Inc. in 2018, a move that significantly strengthened its position in precision diagnostics.
Following the acquisition, Bio-Techne launched the ExoDx Prostate (EPI) Test, one of the first commercially available exosome-based liquid biopsy tests for prostate cancer risk assessment. The non-invasive test analyzes urinary exosomal biomarkers to help physicians determine the likelihood of high-grade prostate cancer without the need for invasive biopsy procedures.
As the only player currently offering approved exosome-based diagnostic products, Bio-Techne has established a dominant position in this rapidly emerging market.
Emerging Players Expand Research and Diagnostic Capabilities
Although Bio-Techne currently dominates commercial diagnostics, several emerging companies are building strong capabilities in exosome isolation, analysis, and therapeutic development.
AMSBIO is recognized for providing advanced life science research reagents and services across genomics, proteomics, stem cell science, and cell culture applications. The company offers a broad portfolio of exosome isolation tools, including reagents, immunobeads, and immunoplates designed for isolating intact exosomes from biological fluids and cell culture media.
Meanwhile, INOVIQ is focusing on precision diagnostics and exosome-based cancer detection technologies. The company commercializes products such as EXO-NET, a pan-exosome capture platform for research applications, and the hTERT test, which supports bladder cancer diagnosis alongside urine cytology testing.
Other notable companies working to expand their market presence include NanoFCM Inc., System Biosciences, LLC., and Capital Biosciences, Inc.. These firms are actively developing exosome isolation kits, liquid biopsy tools, and research-use-only solutions to support academic and clinical research.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198025144
Therapeutics Segment Holds Massive Future Potential
While diagnostics currently dominate the market, exosome therapeutics are expected to create significant future growth opportunities. Researchers are increasingly exploring exosomes as drug delivery vehicles due to their natural ability to transport proteins, RNA, and therapeutic molecules between cells.
Companies such as Capricor Therapeutics, Inc., Evox Therapeutics, and ILIAS Biologics Inc. are investing heavily in next-generation exosome therapeutics targeting oncology, regenerative medicine, and inflammatory diseases.
Future Outlook
The exosome diagnostics and therapeutics market is poised to become one of the fastest-growing segments in biotechnology and precision medicine. Rising demand for minimally invasive diagnostics, advancements in liquid biopsy technologies, and increasing investments in exosome-based therapeutics are expected to accelerate market expansion over the next decade.
As commercialization of exosome therapeutics begins after 2029, the market is likely to witness intense innovation, strategic collaborations, and increased competition among biotechnology companies worldwide.
For more information, inquire now! Inquire Now